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such as improved medication adherence. The objective of this
study was to estimate the impact of type of pharmacy
(chain/independent) on adherence to Oral Hypoglycemic Agents
(OHAs) in patients newly diagnosed with type 2 diabetes.
METHODS: Newly diagnosed type 2 diabetes patients during a
four-year period were identiﬁed from a Medicaid claims data-
base. The provider of the index prescription was classiﬁed as a
chain or independent pharmacy. Utilization patterns (switching,
augmentation, discontinuation, non-modiﬁcation) and adher-
ence to OHAs (Medication Possession Ratios) were computed
for a 12-month follow-up period from the date of the index
OHA prescription. A multivariate framework was used to esti-
mate the impact of type of pharmacy on utilization patterns and
adherence, controlling for demographics, co-morbidity, diabetes
severity, and regimen complexity. RESULTS: A total of 1214
newly diagnosed type-2 diabetes patients were identiﬁed (inde-
pendent pharmacy = 430; chain pharmacy = 784). Utilization
patterns were not signiﬁcantly different between patients ﬁlling
their prescriptions at an independent pharmacy versus those
ﬁlling prescriptions at a chain pharmacy. Independent-sample t-
tests indicated that adherence to OHAs (Mean ± S.D) was sig-
niﬁcantly higher for patients ﬁlling their prescriptions at a
independent pharmacy (0.90 ± 0.11) as compared to those ﬁlling
prescriptions at a chain pharmacy (0.87 ± 0.13) [p = 0.02].
Results of a semi-log OLS model indicated that controlling for
covariates, patients ﬁlling prescriptions at an independent phar-
macy had 2.30% higher adherence to OHAs as compared to
those ﬁlling prescriptions at a chain pharmacy [p = 0.04]. CON-
CLUSION: Patients ﬁlling prescriptions at independent pharma-
cies have signiﬁcantly higher adherence to OHAs as compared
to those ﬁlling prescriptions at chain pharmacies. This improved
adherence may affect glycemic control and consequently inci-
dence of diabetes related complications.
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OBJECTIVES: Long-term adherence to medications among type
2 diabetes patients may have an impact on health care costs and
hospitalizations. This study examined differences in medication
adherence, and persistence, hospitalization and health care costs
between patients with type 2 diabetes enrolled in the North Car-
olina Medicaid newly starting thiazolidinedione (TZD) therapy
and those starting other oral antidiabetic agents. METHODS: A
total of 1774 patients newly starting TZD therapy between July
2001 and June 2002 were compared to 218 patients starting met-
formin and 1199 patients starting sulfonylureas for health care
costs and outcomes in the post-medication start year. The
cohorts were followed for 30 months (July 2002 to December
2004) to examine if there were any differences in outcomes such
as adherence, persistence, hospitalization and total health care
costs that could be associated with type of therapy. Multivariate
regression techniques incorporating health care utilization in the
year prior to start of new therapy were utilized to determine 
the net cost impact of one therapy versus the other. RESULTS:
The average health care costs were less for patients on TZD
[836.34 (1176.30)] as compared to other two groups. Persistence
and adherence rate to TZDs was similar to other Sulfonylureas,
and higher than Metformin. Multivariate analysis showed that
patients on TZD therapy had signiﬁcantly higher medication
adherence while metformin users had signiﬁcantly lower med-
ication adherence as compared to sulfonylureas. Patients on
TZD therapy were associated with decreased likelihood of hos-
pitalization and decreased number of hospitalizations as com-
pared to sulfonylureas users. Adherence to new therapy was
signiﬁcantly associated with decreased number of hospitaliza-
tions. CONCLUSIONS: Long-term use of thiazolidinedione
therapy in a Medicaid-enrolled type 2 diabetic population was
associated with signiﬁcantly greater treatment adherence, and
reduced hospitalization in the post-start year compared to
patients starting other oral antidiabetic agents.
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OBJECTIVE: Medication adherence is an important factor in
improving outcomes among type 2 diabetes patients. The
primary objective of this study was to determine the association
between race and medication adherence among type 2 diabetes
patients. The secondary objectives were to determine the associ-
ation between type of therapy and medication adherence and to
determine if race has an inﬂuence in determining the medication
adherence to speciﬁc antidiabetic therapy. METHODS: This ret-
rospective cohort study was conducted using North Carolina
Medicaid prescription claims. A total of 1774 patients newly
starting Thiazolidinediones were compared to 216 patients start-
ing metformin and 1179 patients starting Sulfonylureas. Med-
ication adherence was measured as Medication Possession Ratio
using prescription reﬁll patterns. Multivariate regression analy-
ses were used to determine the difference in adherence rates
adjusting for other covariates. RESULTS: Whites’ had highest
mean medication adherence rate of 59% which was signiﬁcantly
different from Blacks (54%) (p < 0.05). Thiazolidinediones’
adherence rate of 60% was signiﬁcantly higher than metformin
(22%) and sulfonylurea group (57%) (both p < 0.05). Whites
had higher adherence to all the therapies as compared to other
two races. In multivariate analyses, the adherence rate of black
patients was found to be signiﬁcantly lower by 12% as compared
to whites after adjusting for other variables (p < 0.05). Met-
formin users were associated with 62% decrease in adherence
rate as compared with the sulfonylurea group and 63% decrease
in adherence rate as compared with thiazolidinediones (both p <
0.05). CONCLUSION: Antidiabetic medication adherence was
associated with race as well as type of therapy. Future research
should focus on investigating patient-related and therapy-related
factors affecting medication adherence in type 2 diabetes
patients.
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OBJECTIVE: The purpose of this study was to determine the
extent of adherence among diabetic patients to treatments and
